Protagonist Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders held on June 7, 2019. Protagonist Therapeutics, Inc. is an emerging growth company incorporated in Delaware, with its common stock (PTGX) trading on The Nasdaq Stock Market, LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Two Class III directors were elected to serve until the 2022 Annual Meeting.
- Harold E. Selick, Ph.D.: 16,233,738 votes For; 1,863,379 votes Withheld; 2,525,542 Broker Non-Votes.
- Bryan Giraudo: 12,761,211 votes For; 5,335,906 votes Withheld; 2,525,542 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was approved.
- Votes: 20,556,122 For; 66,537 Against; 0 Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. No other matters were submitted for stockholder action.
Key Facts for Investor Verification
- Confirmation that Harold E. Selick and Bryan Giraudo were successfully elected to the Board of Directors.
- Verification that PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2019.
- Review of the definitive proxy statement filed on April 26, 2019, for detailed background on the nominees and auditor selection.